As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Benitec Biopharma Inc. The largest reported stake is Suvretta Capital Management, LLC's, at 44.1%. 7 filings are on record since August 14, 2025 (Schedule 13D/A, November 10, 2025).
Sell to companies like Benitec Biopharma Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Franklin Resources, Inc. · Sole voting: 3,751,709 · Shared voting: 0 · Sole dispositive: 3,751,709 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-01-29
- · Reporting person: Janus Henderson Group Plc · Sole voting: 0 · Shared voting: 3,382,836 · Sole dispositive: 0 · Shared dispositive: 3,382,836 · SCHEDULE 13G/A, 2025-12-08
- · Reporting person: RA Capital Management, L.P. · Sole voting: 0 · Shared voting: 1,850,000 · Sole dispositive: 0 · Shared dispositive: 1,850,000 · SCHEDULE 13G, 2025-12-03
- · Reporting person: Suvretta Capital Management, LLC · Sole voting: 0 · Shared voting: 17,761,945 · Sole dispositive: 0 · Shared dispositive: 17,761,945 · SCHEDULE 13D/A, 2025-11-10
- · Holder: Franklin Resources, Inc. · Percent: 14.9% · SCHEDULE 13G/A
Benitec Biopharma Inc. has 7 Schedule 13D or 13G filings on record since 2025-08-14. 4 holders' latest filing reports 5% or more of common stock, par value $0.0001. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 44.1% | 17,761,945 | SCHEDULE 13D/A, 2025-11-10 | 2025-11-07 |
| Franklin Resources, Inc. | 10.6% | 3,751,709 | SCHEDULE 13G/A, 2026-01-29 | 2025-12-31 |
| Janus Henderson Group Plc | 9.99% | 3,382,836 | SCHEDULE 13G/A, 2025-12-08 | 2025-11-28 |
| RA Capital Management, L.P. | 5.5% | 1,850,000 | SCHEDULE 13G, 2025-12-03 | 2025-11-07 |
Holding shares or following this stake? See who's behind Benitec Biopharma Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Benitec Biopharma Inc. and the records around it.
Benitec Biopharma Inc. elsewhere on the record
- Leadership changes May 2026
- Who owns it
Companies that share a holder
- SUVRETTA CAPITAL MANAGEMENT, LLC also filed stake reports on 22 other companies: Veradermics, Inc (Aug 2026), Abeona Therapeutics Inc. (Aug 2026), Fulcrum Therapeutics, Inc. (Aug 2026)
- Franklin Resources, Inc. also filed stake reports on 41 other companies: Adicet Bio, Inc. (Oct 2026), ALBEMARLE CORPORATION (Oct 2026), Andersen Group Inc. (Oct 2026)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026), SOLID BIOSCIENCES INC. (Nov 2026)
Watch Benitec Biopharma Inc.
Get an email when Benitec Biopharma Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Benitec Biopharma Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Benitec Biopharma Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Benitec Biopharma Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Suvretta Capital Management, LLC | 0 | 17,761,945 | 0 | 17,761,945 | SCHEDULE 13D/A, 2025-11-10 |
| Averill Master Fund, Ltd. | 0 | 15,237,643 | 0 | 15,237,643 | SCHEDULE 13D/A, 2025-11-10 |
| Averill Madison Master Fund, Ltd. | 0 | 2,524,302 | 0 | 2,524,302 | SCHEDULE 13D/A, 2025-11-10 |
| Aaron Cowen | 0 | 17,761,945 | 0 | 17,761,945 | SCHEDULE 13D/A, 2025-11-10 |
| Franklin Resources, Inc. | 3,751,709 | 0 | 3,751,709 | 0 | SCHEDULE 13G/A, 2026-01-29 |
| Charles B. Johnson | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-01-29 |
| Rupert H. Johnson, Jr. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-01-29 |
| Franklin Advisers, Inc. | 3,751,709 | 0 | 3,751,709 | 0 | SCHEDULE 13G/A, 2026-01-29 |
| Janus Henderson Group Plc | 0 | 3,382,836 | 0 | 3,382,836 | SCHEDULE 13G/A, 2025-12-08 |
| Janus Henderson Biotech Innovation Master Fund Ltd | 0 | 2,067,781 | 0 | 2,067,781 | SCHEDULE 13G/A, 2025-12-08 |
| RA Capital Management, L.P. | 0 | 1,850,000 | 0 | 1,850,000 | SCHEDULE 13G, 2025-12-03 |
| Peter Kolchinsky | 0 | 1,850,000 | 0 | 1,850,000 | SCHEDULE 13G, 2025-12-03 |
| Rajeev Shah | 0 | 1,850,000 | 0 | 1,850,000 | SCHEDULE 13G, 2025-12-03 |
| RA Capital Healthcare Fund, L.P. | 0 | 1,850,000 | 0 | 1,850,000 | SCHEDULE 13G, 2025-12-03 |
The latest filing names Benitec Biopharma Inc., with its principal executive office as 3940 Trust Way, Hayward, CA 94545 (SCHEDULE 13G/A, 2026-01-29).
What the percentages are based on
Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of shares of common stock of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.RA Capital Management, L.P., SCHEDULE 13G, 2025-12-03
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Janus Henderson Group Plc | 11.3% | SCHEDULE 13G/A |
| 2025-08-14 | Janus Henderson Group Plc | 11.3% | SCHEDULE 13G/A |
| 2025-11-04 | Franklin Resources, Inc. | 14.9% | SCHEDULE 13G/A |
| 2025-11-10 | Suvretta Capital Management, LLC | 44.1% | SCHEDULE 13D/A |
| 2025-12-03 | RA Capital Management, L.P. | 5.5% | SCHEDULE 13G |
| 2025-12-08 | Janus Henderson Group Plc | 9.99% | SCHEDULE 13G/A |
| 2026-01-29 | Franklin Resources, Inc. | 10.6% | SCHEDULE 13G/A |
Questions about who owns Benitec Biopharma Inc.
Who owns Benitec Biopharma Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Benitec Biopharma Inc.: Suvretta Capital Management, LLC (44.1%, Schedule 13D/A, filed 2025-11-10), Franklin Resources, Inc. (10.6%, Schedule 13G/A, filed 2026-01-29), Janus Henderson Group Plc (9.99%, Schedule 13G/A, filed 2025-12-08) and RA Capital Management, L.P. (5.5%, Schedule 13G, filed 2025-12-03).
Who are the largest shareholders of Benitec Biopharma Inc.?
By the share each holder's latest filing reports, the largest holders of Benitec Biopharma Inc. on this page are Suvretta Capital Management, LLC (44.1%), Franklin Resources, Inc. (10.6%) and Janus Henderson Group Plc (9.99%).
When did Suvretta Capital Management, LLC buy into Benitec Biopharma Inc.?
The filings give report dates, not purchase dates. The earliest filing from Suvretta Capital Management, LLC on this page is the Schedule 13D/A, filed 2025-11-10, reporting 44.1%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Benitec Biopharma Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 29, 2026 | Leadership change: David Friedman appointed, Director | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Benitec Biopharma Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.